logo-loader
viewCellectar Biosciences

Cellectar shares extend last Friday's 400% surge

Cellectar Biosciences shares advance by 20% - extending in small measure on the 400% leap seen on Friday after its phospholipid ether analogs as cancer-targeting drug vehicles received their US Patent and Trademarks

rsz_shutterstock_79850125.jpg
Patents received give boost

Cellectar Biosciences Inc (NASDAQ:CLRB) shares advanced by 20% on Monday - extending in small measure on the 400% leap seen on Friday.

Investors became excited last week that Cellectar's phospholipid ether analogs as cancer-targeting drug vehicles had received their US Patent and Trademarks.

The latest surge in the share price followed news that Cellectar chief executive, Jim Caruso, would be presenting at the 2016 Marcum MicroCap Conference in New York on 2 June.

Caruso intends to use the conference as a platform to publicise the group's phospholid drug conjugate platform.

The shares were last seen up 19.6% at $4.13.

Quick facts: Cellectar Biosciences

Price: 1.03 USD

NASDAQ:CLRB
Market: NASDAQ
Market Cap: $9.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arizona Silver Exploration will be going back to Philadelphia after drilling...

Arizona Silver Exploration (TSXV: AZS) (OTCQB: AZASF) VP of Exploration Greg Hahn joined Steve Darling from Proactive with some results from the company’s drill program at their Philadelphia project. Hahn discusses the next step the company is planning. Hahn also told Proactive they are...

11 hours ago

2 min read